The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1449
August 18, 2014
View Complete Issue         Table of Contents 2019 
A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention
August 18, 2014 (Issue: 1449)
The FDA has approved the use of a transcutaneous electrical nerve stimulation device (Cefaly – Cefaly Technology) for prevention of episodic migraine in patients ≥18 years old. The first device to be approved in the US for migraine...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention
Article code: 1449d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.